Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients

BACKGROUND: Interstitial pneumonia (IP) is a common and fatal adverse effect of rituximab-containing immunochemotherapy in lymphoma patients. Following prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX), the clinical features, treatment, and risk factors for IP development remain la...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cong, Lu, Fangxiao, Lei, Tao, Yu, Haifeng, Yang, Haiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797998/
https://www.ncbi.nlm.nih.gov/pubmed/35117880
http://dx.doi.org/10.21037/tcr-20-988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797998/
https://www.ncbi.nlm.nih.gov/pubmed/35117880
http://dx.doi.org/10.21037/tcr-20-988

Ejemplares similares